keyword
MENU ▼
Read by QxMD icon Read
search

Ulcerative colitis tnf

keyword
https://www.readbyqxmd.com/read/28630047/update-on-anti-tumor-necrosis-factor-agents-and-other-new-drugs-for-inflammatory-bowel-disease
#1
REVIEW
Benjamin L Cohen, David B Sachar
The treatment of inflammatory bowel disease (IBD)-ulcerative colitis (UC) and Crohn's disease (CD)-has evolved beyond surgery with the introduction of biologic agents, primarily antibodies against mediators of inflammation and cell attraction. Anti-tumor necrosis factor (TNF) agents have been the first line treatment for moderate to severe ulcerative colitis and Crohn's disease for more than 15 years. During that time much has been learnt about how best to use these agents. This review will assess the evidence on how to optimize the use of anti-TNF agents; when and how to start treatment; how to monitor treatment and when to de-escalate it; and the potential adverse effects of these drugs...
June 19, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28625817/natural-history-of-adult-ulcerative-colitis-in-population-based-cohorts-a-systematic-review
#2
Mathurin Fumery, Siddharth Singh, Parambir S Dulai, Corinne Gower-Rousseau, Laurent Peyrin-Biroulet, William J Sandborn
INTRODUCTION: A comprehensive knowledge of the natural history of UC helps understand disease evolution, identify poor prognostic markers and impact of treatment strategies and facilitates shared decision-making. We systematically reviewed the natural history of UC in adult population-based cohort studies with long-term follow-up. MATERIALS AND METHODS: Through a systematic literature review of MEDLINE through March 31, 2016, we identified 60 studies performed in 17 population-based inception cohorts reporting the long-term course and outcomes of adult-onset UC (n=15,316 UC patients)...
June 15, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28622083/the-importance-of-considering-differences-in-study-design-in-network-meta-analysis-an-application-using-anti-tumor-necrosis-factor-drugs-for-ulcerative-colitis
#3
Chris Cameron, Emmanuel Ewara, Florence R Wilson, Abhishek Varu, Peter Dyrda, Brian Hutton, Michael Ingham
BACKGROUND AND AIMS: Adaptive trial designs present a methodological challenge when performing network meta-analysis (NMA), as data from such adaptive trial designs differ from conventional parallel design randomized controlled trials (RCTs). We aim to illustrate the importance of considering study design when conducting an NMA. METHODS: Three NMAs comparing anti-tumor necrosis factor drugs for ulcerative colitis were compared and the analyses replicated using Bayesian NMA...
June 1, 2017: Medical Decision Making: An International Journal of the Society for Medical Decision Making
https://www.readbyqxmd.com/read/28619075/anti-inflammatory-effect-of-chang-an-shuan-on-tnbs-induced-experimental-colitis-in-rats
#4
Hong Mi, Feng-Bin Liu, Hai-Wen Li, Jiang-Tao Hou, Pei-Wu Li
BACKGROUND: Inflammatory bowel disease (IBD), denominated by Crohn's disease and ulcerative colitis, is often associated with abdominal pain, diarrhea and bloody stool. The standard protocols for treating colitis conditions are not satisfactory; thus, complementary and alternative medicines have been increasingly accepted by IBD sufferers worldwide. In this study, we aimed to elucidate the anti-inflammatory effect of Chang-An-Shuan (CAS), a 6-herb Chinese medicinal formula, on 2, 4, 6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in rats and the underlying mechanisms...
June 15, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/28617757/looking-into-enteric-virome-in-patients-with-ibd-defining-guilty-or-innocence
#5
Susana Lopes, Patricia Andrade, Silvia Conde, Rodrigo Liberal, Cláudia C Dias, Salomão Fernandes, Jorge Pinheiro, Joana S Simões, Fátima Carneiro, Fernando Magro, Guilherme Macedo
BACKGROUND: Although there is some evidence suggesting that certain viruses may be involved in the onset of inflammatory bowel disease (IBD), data regarding viral prevalence and viral load in blood and mucosa of patients with IBD are scarce. The main aim of this study is to evaluate the prevalence and viral load of common Epstein-Barr virus (EBV), cytomegalovirus (CMV), and human herpes virus 6 in blood and mucosa of adult patients with endoscopic active IBD. METHODS: From January to December 2014, ulcerative colitis and Crohn's disease patients with active endoscopic disease were consecutively enrolled...
June 14, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28617055/new-treatment-strategies-for-ulcerative-colitis
#6
Julian Panés, Ignacio Alfaro
Therapeutic strategies in ulcerative colitis are evolving. A personalized and optimal use of available drugs and the integration of new drug classes are the cornerstones underpinning the new treatment paradigms. Areas covered: A structured literature search in Medline and PubMed, Cochrane meta-analyses, and abstracts of international congresses has been performed to review therapeutic approaches to ulcerative colitis. The primary therapeutic objective of therapy is to achieve clinical remission since persistence of active disease, even if mild, leads to a significant reduction in quality of life...
June 21, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28614561/association-of-preoperative-anti-tumor-necrosis-factor-therapy-with-adverse-postoperative-outcomes-in-patients-undergoing-abdominal-surgery-for-ulcerative-colitis
#7
Audrey S Kulaylat, Afif N Kulaylat, Eric W Schaefer, Andrew Tinsley, Emmanuelle Williams, Walter Koltun, Christopher S Hollenbeak, Evangelos Messaris
Importance: Despite the increasing use of anti-tumor necrosis factor (TNF) therapy in ulcerative colitis, its effects on postoperative outcomes remain unclear, with many patients requiring surgical intervention despite optimal medical management. Objective: To assess the association of preoperative use of anti-TNF agents with adverse postoperative outcomes. Design, Setting, and Participants: This analysis used insurance claims data from a large national database to identify patients 18 years or older with ulcerative colitis...
June 14, 2017: JAMA Surgery
https://www.readbyqxmd.com/read/28601639/tofacitinib-ameliorates-atherosclerosis-and-reduces-foam-cell-formation-in-apoe-deficient-mice
#8
Zaicun Wang, Shumei Wang, Zunzhe Wang, Tiantian Yun, Chenchen Wang, Huating Wang
Atherosclerosis is a chronic inflammatory cardiovascular disease with high mortality worldwide. Tofacitinib (CP-690,550), an oral small-molecule Janus kinase inhibitor, has been shown to be effective in the treatment of rheumatoid arthritis, autoimmune encephalomyelitis and ulcerative colitis. However, its protective effect against atherosclerosis remains poorly understood. The aim of the present study was to evaluate the effects of Tofacitinib on atherogenic diet (ATD)-induced atherosclerosis using apolipoprotein E deficient (apoE-/-) mice...
June 8, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28600438/human-rela-haploinsufficiency-results-in-autosomal-dominant-chronic-mucocutaneous-ulceration
#9
Yousef R Badran, Fatma Dedeoglu, Juan Manuel Leyva Castillo, Wayne Bainter, Toshiro K Ohsumi, Athos Bousvaros, Jeffrey D Goldsmith, Raif S Geha, Janet Chou
The treatment of chronic mucocutaneous ulceration is challenging, and only some patients respond selectively to inhibitors of tumor necrosis factor-α (TNF). TNF activates opposing pathways leading to caspase-8-mediated apoptosis as well as nuclear factor κB (NF-κB)-dependent cell survival. We investigated the etiology of autosomal-dominant, mucocutaneous ulceration in a family whose proband was dependent on anti-TNF therapy for sustained remission. A heterozygous mutation in RELA, encoding the NF-κB subunit RelA, segregated with the disease phenotype and resulted in RelA haploinsufficiency...
June 9, 2017: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/28597827/inflammatory-bowel-disease-in-childhood-and-adolescence
#10
Jan Däbritz, Patrick Gerner, Axel Enninger, Martin Claßen, Michael Radke
BACKGROUND: The incidence of inflammatory bowel disease (IBD) in childhood and adolescence is 5-11 cases per 100 000 persons per year, corresponding to a new diagnosis of IBD in 800-1470 patients in Germany each year. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed, including guidelines from Germany and abroad. RESULTS: Children and adolescents with IBD often have extensive involvement and an aggressive course of disease...
May 12, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28595382/anti-inflammatory-properties-of-bifidobacterium-longum-expressing-human-manganese-superoxide-dismutase-using-the-tnbs-induced-rats-model-of-colitis
#11
Yajie Xie, Qing Guo, Shiyu Li, Mengge Liu, Qian Zhang, Zhenrui Xu, Hanxiao Sun
The chronic enteritis disease ulcerative colitis (UC) is a formidable opponent, and its etiology remains unclear. Current studies have shown that oxidative stress is closely related to the pathogenesis of inflammatory bowel disease. Antioxidant enzymes, such as manganese superoxide dismutase (MnSOD),have been deemed to exert an anti-inflammatory function. Normally, oral administration of MnSOD directly leads to an incapacitation because of poor penetration and stability. To address this problem, the probiotic Bifidobacterium longum (B...
June 8, 2017: Journal of Microbiology and Biotechnology
https://www.readbyqxmd.com/read/28593685/one-year-effectiveness-and-safety-of-vedolizumab-therapy-for-inflammatory-bowel-disease-a-prospective-multicentre-cohort-study
#12
A Amiot, M Serrero, L Peyrin-Biroulet, J Filippi, B Pariente, X Roblin, A Buisson, C Stefanescu, C Trang-Poisson, R Altwegg, P Marteau, T Vaysse, A Bourrier, S Nancey, D Laharie, M Allez, G Savoye, J Moreau, L Vuitton, S Viennot, A Aubourg, A-L Pelletier, G Bouguen, V Abitbol, C Gagniere, Y Bouhnik
BACKGROUND: We recently showed that vedolizumab is effective in patients with Crohn's disease (CD) and ulcerative colitis (UC) with prior anti-TNF failure in a multicentre compassionate early-access programme before marketing authorisation was granted to vedolizumab. AIMS: To assess effectiveness and safety of vedolizumab at week 54 in patients UC and CD. METHODS: Between June and December 2014, 173 patients with Crohn's disease (CD) and 121 with ulcerative colitis (UC) were treated with vedolizumab induction therapy...
June 8, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28590340/colonic-phenotypes-are-associated-with-poorer-response-to-anti-tnf-therapies-in-patients-with-ibd
#13
Soon Man Yoon, Talin Haritunians, Sultan Chhina, Zhenqiu Liu, Shaohong Yang, Carol Landers, Dalin Li, Byong Duk Ye, David Shih, Eric A Vasiliauskas, Andrew Ippoliti, Shervin Rabizadeh, Stephan R Targan, Gil Y Melmed, Dermot P B McGovern
BACKGROUND: Although anti-tumor necrosis factor (TNF) agents are effective in patients with inflammatory bowel disease (IBD), many patients either do not respond to anti-TNF treatment or lose response over time. The aim of this study was to determine factors associated with response to anti-TNF therapy in IBD. METHODS: Patients with Crohn's disease (CD) or ulcerative colitis who had consented to participate in a genetics registry and been treated with anti-TNF agents were evaluated retrospectively and categorized as primary nonresponders or secondary nonresponders...
June 5, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28588888/thioguanine-in-inflammatory-bowel-disease-long-term-efficacy-and-safety
#14
Mark G Ward, Kamal V Patel, Viraj C Kariyawasam, Rishi Goel, Ben Warner, Tim R Elliott, Paul A Blaker, Peter M Irving, Anthony M Marinaki, Jeremy D Sanderson
BACKGROUND: Thioguanine (TG) is efficacious in inflammatory bowel disease (IBD), but its toxicity, particularly nodular regenerative hyperplasia (NRH) of the liver, has limited its use. We assessed the long-term clinical outcomes and safety of TG in patients whom were intolerant or refractory to conventional immunomodulators. METHODS: This is a retrospective, single-centre study of IBD patients treated with TG from 2001-2013. Response was defined as clinical remission (Harvey-Bradshaw Index < 5 for Crohn's disease (CD), Simple Clinical Colitis Activity Index < 4 for ulcerative colitis (UC)) without corticosteroids or, if receiving anti-tumour-necrosis-factor (anti-TNF) therapy, absence of dose escalation...
June 2017: United European Gastroenterology Journal
https://www.readbyqxmd.com/read/28584644/evaluation-of-tumor-necrosis-factor-tnf-%C3%AE-mrna-expression-level-and-the-rs1799964-polymorphism-of-the-tnf-%C3%AE-gene-in-peripheral-mononuclear-cells-of-patients-with-inflammatory-bowel-diseases
#15
Mahyar Nourian, Vahid Chaleshi, Leila Pishkar, Pedram Azimzadeh, Shaghayegh Baradaran Ghavami, Hedieh Balaii, Samaneh Alinaghi, Shabnam Shahrokh, Hamid Asadzadeh Aghdaei, Mohammad Reza Zali
Crohn's disease (CD) and ulcerative colitis (UC) are types of chronic inflammatory bowel disease (IBD) of which the actual causes remain unknown. Emerging data indicate that alterations in cytokine synthesis may be involved in IBD pathogenesis. The aim of the present study was to determine whether the tumor necrosis factor (TNF)-α mRNA expression level and rs1799964 polymorphism are the genetic susceptibility component of IBD development. The TNF-α mRNA expression level of peripheral blood mononuclear cells (PBMCs) was measured using comparative reverse-transcription quantitative polymerase chain reaction (PCR)...
June 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28581039/efficacy-of-cytapheresis-for-remission-induction-and-dermatological-manifestations-of-ulcerative-colitis
#16
Osamu Nomura, Taro Osada, Tomoyoshi Shibuya, Dai Ishikawa, Keiichi Haga, Tomohiro Kodani, Naoto Sakamoto, Tatsuo Ogihara, Ken Yamaji, Sumio Watanabe
BACKGROUND: In ulcerative colitis (UC) patients, cytapheresis depletes elevated and activated leucocytes, which are known to release inflammatory cytokines including tumor necrosis factor (TNF)-α. Further, there are UC patients who develop erythema nodosum (EN) or pyoderma gangrenosum (PG) as extra-intestinal manifestations of UC. METHODS: Between 2008 and 2015, 181 consecutive patients with active UC received cytapheresis with either a granulocyte and monocyte apheresis (GMA) column or with a leucocyte removal filter (LCAP) as remission induction therapy...
June 5, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28580313/the-effect-of-inflammatory-status-on-butyrate-and-folate-uptake-by-tumoral-caco-2-and-non-tumoral-iec-6-intestinal-epithelial-cells
#17
Mafalda R Couto, Pedro Gonçalves, Telmo A Catarino, Fátima Martel
OBJECTIVE: Colorectal cancer (CRC) is the second leading cause of cancer death in occidental countries. Chronic inflammatory bowel disease (crohn's disease and ulcerative colitis) is associated with an increased risk for CRC development. The aim of this work was to investigate the relationship between inflammatory status and absorption of nutrients with a role in CRC pathogenesis. MATERIALS AND METHODS: In this experimental study, we evaluated the in vitro effect of tumour necrosis factor-alpha (TNF-α), interferon-γ (IF-γ), and acetylsalicylic acid on 14C-butyrate (14C- BT), 3H-folic acid (3H-FA) uptake, and on proliferation, viability and differentiation of Caco-2 and IEC-6 cells in culture...
2017: Cell Journal
https://www.readbyqxmd.com/read/28577692/ulcerative-colitis-treatment-patterns-and-cost-of-care
#18
Kyle D Null, Yihua Xu, Margaret K Pasquale, Chinyu Su, Amy Marren, James Harnett, Jack Mardekian, Alireza Manuchehri, Paul Healey
OBJECTIVES: To examine treatment patterns, dosing, health care resource utilization, and cost of tumor necrosis factor inhibitors (TNFi), adalimumab (ADA) and infliximab (IFX), among patients enrolled in US Humana insurance plans who have been diagnosed with ulcerative colitis (UC). METHODS: This retrospective cohort study identified the first pharmacy or medical claim for ADA or IFX (from January 1, 2007, to December 31, 2014) in patients with continuous enrollment for 6 months or more preindex and 12 months or more postindex, with one or more UC diagnosis claim 6 months pre- or postindex...
June 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28560286/uncovering-pathogenic-mechanisms-of-inflammatory-bowel-disease-using-mouse-models-of-crohn-s-disease-like-ileitis-what-is-the-right-model
#19
REVIEW
Fabio Cominelli, Kristen O Arseneau, Alexander Rodriguez-Palacios, Theresa T Pizarro
Crohn's disease and ulcerative colitis, together known as inflammatory bowel disease, are debilitating chronic disorders of unknown cause and cure. Our evolving understanding of these pathologies is enhanced greatly by the use of animal models of intestinal inflammation that allow in vivo mechanistic studies, preclinical evaluation of new therapies, and investigation into the causative factors that underlie disease pathogenesis. Several animal models, most commonly generated in mice, exist for the study of colitis...
July 2017: Cellular and Molecular Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28556814/combined-treatment-with-hyaluronic-acid-and-mesalamine-protects-rats-from-inflammatory-bowel-disease-induced-by-intracolonic-administration-of-trinitrobenzenesulfonic-acid
#20
Chih-Tung Chiu, Sheng-Nan Kuo, Shao-Wen Hung, Cheng-Yao Yang
Drugs such as mesalamine (5-ASA) are currently recommended for the treatment of inflammatory bowel disease (IBD). To reduce the frequency of their administration and improve their therapeutic effect, this study investigated the adhesion efficacy, wound healing promotion, and decrease in inflammation in ulcers in the colonic tissue of rats with colitis after combined treatment with hyaluronic acid (HA) and 5-ASA (IBD98-M). HA-fluoresceinamine (FL) conjugates successfully adhered to the mucosal layer and were conjugated in the vascular tissue...
May 30, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
keyword
keyword
22393
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"